Opiates as antidepressants

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1612-1622

  Berrocoso, Esther ^a,b   Sánchez Blázquez, Pilar ^b,c   Garzón, Javier ^b,c   Mico, Juan A ^a,b  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO CAJAL   (Spain)

Author keywords

(DOP receptor); (KOP receptor); (MOP receptor); Antidepressant; Depression; Monoamines; Opiate; Opioid

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BW 373U 86; DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN 2; DESIPRAMINE; DIZOCILPINE; DYNORPHIN DERIVATIVE; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FLUOXETINE; IMIPRAMINE; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LEVORPHANOL; MCL 144B; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NORBINALTORPHIMINE; OPIATE DERIVATIVE; SALVORIN A; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANXIETY DISORDER; BRAIN REGION; CANCER PAIN; CHRONIC DRUG ADMINISTRATION; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSPHORIA; FORCED SWIMMING TEST; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; HYPOTHERMIA; LEARNED HELPLESSNESS; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; MOOD DISORDER; NEUROPATHIC PAIN; NEUROPATHOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; REMISSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SUICIDAL IDEATION; TAIL SUSPENSION TEST; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; RECEPTORS, OPIOID;

EID: 67650602317     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168100     Document Type: Review

References (149)

1. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.
3. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59(Suppl 14): 11-4.
4. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008; 69(Suppl E1): 4-7.
5. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006; 163: 1905-17.
6. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep 2007; 9: 449-59.
7. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370.
8. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
9. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005; 10: 578-85.
10. Extein I, Pottash ALC, Gold MS. In: Verebey K, Ed. Opioids in mental illness: Theories, clinical observations and treatment possibilities, The New York Academy of Sciences: New York 1982; vol. 398, pp. 113-9.
11. Emrich HM, Vogt P, Herz A. In: Verebey K, Ed. Opioids in mental illness: Theories, clinical observations and treatment possibilities, The New York Academy of SciPnces: New York 1982; vol. 398: pp. 108-12.
12. Kraepelin E. Einführung in die psychiatrische klinik. Ambrosius Barth-Verlag: Leipzig 1901.
13. Milligan G, Murdoch H, Kellett E, White JH, Feng GJ. Interactions between G-protein-coupled receptors and periplakin: A selective means to regulate G-protein activation. Biochem Soc Trans 2004; 32: 878-80.
14. Pert CB, Snyder SH. Opiate receptor: Demonstration in nervous tissue. Science 1973; 179: 1011-4.
15. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: The exciting but vain quest for the Holy Grail. Br J Pharmacol 2006; 147(Suppl 1): S153-62.
16. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73: 953-90.
17. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351-69.
18. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567-92.
19. Sanchez-Blazquez P, Rodriguez-Diaz M, Frejo MT, Garzon J. Stimulation of mu- and delta-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: Evidence for subtypes of delta-receptors. Eur J Neurosci 1999; 11: 2059-64.
20. Portoghese PS. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 2001; 44: 2259-69.
21. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-208.
22. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995; 15: 49-57.
23. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry 1999; 156: 2017.
24. Darko DF, Risch SC, Gillin JC, Golshan S. Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry 1992; 149: 1162-7.
25. Djurovic D, Milic-Askrabic J, Majkic-Singh N. Serum beta-endorphin level in patients with depression on fluvoxamine. Farmaco 1999; 54: 130-3.
26. Besson A, Privat AM, Eschalier A, Fialip J. Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats. Psychopharmacology (Berl) 1996; 123: 71-8.
27. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 1995; 52: 145-52.
28. Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA. Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci 2002; 72: 143-52.
29. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502.
30. Fichna J, Janecka A, Piestrzeniewicz M, Costentin J, do Rego JC. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 2007; 32: 813-21.
31. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 2000; 25: 195-200.
32. Tao R, Ma Z, Auerbach SB. Differential regulation of 5-hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats. Br J Pharmacol 1996; 119: 1375-84.
33. Tao R, Auerbach SB. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 1995; 68: 553-61.
34. Diez-Guerra FJ, Augood S, Emson PC, Dyer RG. Opioid peptides inhibit the release of noradrenaline from slices of rat medial preoptic area. Exp Brain Res 1987; 66: 378-84.
35. Hagan RM, Hughes IE. Opioid receptor sub-types involved in the control of transmitter release in cortex of the brain of the rat. Neuropharmacology 1984; 23: 491-5.
36. Peoples RW, Giridhar J, Isom GE. Gamma-aminobutyric acidA (GABAA) receptor modulation of morphine inhibition of norepinephrine release. Biochem Pharmacol 1991; 42(Suppl): S121-6.
37. Werling LL, Brown SR, Cox BM. Opioid receptor regulation of the release of norepinephrine in brain. Neuropharmacology 1987; 26: 987-96.
38. Fiber JM, Etgen AM. Modulation of GABA-augmented norepinephrine release in female rat brain slices by opioids and adenosine. Neurochem Res 2001; 26: 853-8.
39. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988; 38: 877-80.
40. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85.
41. Bamigbade TA, Davidson C, Langford RM, Stamford JA. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 1997; 79: 352-6.
42. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Compl 2000; 14: 65-70.
43. Flohe L, Arend I, Cogal A, Richter W, Simon W. [Clinical study on the development of dependency after long-term treatment with tramadol (author's transl)]. Arzneimittelforschung 1978; 28: 213-7.
44. Richter W, Barth H, Flohe L, Giertz H. Clinical investigation on the development of dependence during oral therapy with tramadol. Arzneimittelforschung 1985; 35: 1742-4.
45. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006; 3: CD003726.
46. Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy. J Clin Psychiatry 2001; 62: 205-6.
47. Spencer C. The efficacy of intramuscular tramadol as a rapid-onset antidepressant. Aust N Z J Psychiatry 2000; 34: 1032-3.
48. Fanelli J, Montgomery C. Use of the analgesic tramadol in antidepressant potentiation. Psychopharmacology Bulletin 1998; 32: 442.
49. Shapira NA, Keck PE, Jr., Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997; 6: 170-3.
50. Shapira NA, McConville BJ, Pagnucco ML, Norman AB, Keck PE, Jr. Novel use of tramadol hydrochloride in the treatment of Tourette's syndrome. J Clin Psychiatry 1997; 58: 174-5.
51. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Tramadol induces antidepressant-type effects in mice. Life Sci 1998; 63: PL175-80.
52. Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav Pharmacol 2007; 18: 623-31.
53. Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA. Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: Comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol 2004; 18: 404-11.
54. Hopwood SE, Owesson CA, Callado LF, McLaughlin DP, Stamford JA. Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function. J Psychopharmacol 2001; 15: 147-53.
55. Faron-Gorecka A, Kusmider M, Inan SY, Siwanowicz J, Dziedzicka-Wasylewska M. Effects of tramadol on alpha2-adrenergic receptors in the rat brain. Brain Res 2004; 1016: 263-7.
56. Faron-Gorecka A, Kusmider M, Inan SY, Siwanowicz J, Piwowarczyk T, Dziedzicka-Wasylewska M. Long-term exposure of rats to tramadol alters brain dopamine and alpha 1-adrenoceptor function that may be related to antidepressant potency. Eur J Pharmacol 2004; 501: 103-10.
57. Berrocoso E, Mico JA, Ugedo L. In vivo effect of tramadol on locus coeruleus neurons is mediated by alpha2-adrenoceptors and modulated by serotonin. Neuropharmacology 2006; 51: 146-53.
58. Jiang Q, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI, et al. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 1991; 257: 1069-75.
59. Brandt MR, Furness MS, Rice KC, Fischer BD, Negus SS. Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther 2001; 299: 629-37.
60. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991; 258: 299-303.
61. Nadal X, Banos JE, Kieffer BL, Maldonado R. Neuropathic pain is enhanced in delta-opioid receptor knockout mice. Eur J Neurosci 2006; 23: 830-4.
62. Fraser GL, Gaudreau GA, Clarke PB, Menard DP, Perkins MN. Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation. Br J Pharmacol 2000; 129: 1668-72.
63. Porreca F, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther 1992; 263: 147-52.
64. Cheng PY, Wu D, Soong Y, McCabe S, Decena JA, Szeto HH. Role of mu 1- and delta-opioid receptors in modulation of fetal EEG and respiratory activity. Am J Physiol 1993; 265: R433-8.
65. Hudzik TJ, Howell A, Payza K, Cross AJ. Antiparkinson potential of delta-opioid receptor agonists. Eur J Pharmacol 2000; 396: 101-7.
66. Jutkiewicz EM. The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 2006; 6: 162-9.
67. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 1996; 383: 535-8.
68. Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, et al. Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci USA 2001; 98: 1958-63.
69. Tejedor-Real P, Mico JA, Smadja C, Maldonado R, Roques BP, Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 1998; 354: 1-7.
70. Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 2006; 1069: 172-81.
71. Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC, et al. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol 1992; 216: 157-66.
72. Jutkiewicz EM, Eller EB, Folk JE, Rice KC, Traynor JR, Woods JH. Delta-opioid agonists: Differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther 2004; 309: 173-81.
73. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 2002; 26: 744-55
74. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 2004; 95: 374-80.
75. Saitoh A, Yamada M, Yamada M, Takahashi K, Yamaguchi K, Murasawa H, et al. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4- (2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N- diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res 2008; 1208: 160-9.
76. Jenny M, Winkler C, Spetea M, Schennach H, Schmidhammer H, Fuchs D. Non-peptidic delta-opioid receptor antagonists suppress mitogen-induced tryptophan degradation in peripheral blood mononuclear cells in vitro. Immunol Lett 2008; 118: 82-7.
77. Spina L, Longoni R, Mulas A, Chang KJ, Di Chiara G. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 1. Locomotion, rearing and stereotypies in intact rats. Behav Pharmacol 1998; 9: 1-8.
78. Negus SS, Gatch MB, Mello NK. Discriminative stimulus effects of a cocaine/heroin "speedball" combination in rhesus monkeys. J Pharmacol Exp Ther 1998; 285: 1123-36.
79. Longoni R, Cadoni C, Mulas A, Di Chiara G, Spina L. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats. Behav Pharmacol 1998; 9: 9-14.
80. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: A critical overview. Pharmacol Rev 2006; 58: 115-34.
81. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-5.
82. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189-99.
83. Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 2004; 29: 649-59.
84. Torregrossa MM, Folk JE, Rice KC, Watson SJ, Woods JH. Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. Psychopharmacology (Berl) 2005; 183: 31-40.
85. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) 2002; 164: 42-8.
86. Chipkin RE, Coffin VL. Analgesic and acute central nervous system side effects of the intravenously administered enkephalinase inhibitor SCH 32615. Pharmacol Biochem Behav 1991; 38: 21-7.
87. Stutzmann JM, Bohme GA, Roques BP, Blanchard JC. Differential electrographic patterns for specific mu- and delta-opioid peptides in rats. Eur J Pharmacol 1986; 123: 53-9.
88. De Sarro GB, Marra R, Spagnolo C, Nistico G. Delta opioid receptors mediate seizures produced by intrahippocampal injection of ala-deltorphin in rats. Funct Neurol 1992; 7: 235-8.
89. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
90. Leander JD. A kappa opioid effect: Increased urination in the rat. J Pharmacol Exp Ther 1983; 224: 89-94.
91. Fjalland B, Christensen JD. Kappa-opioid receptor agonists differentially affect the release of neurohypophysial hormones. Pharmacol Toxicol 1990; 66: 176-8.
92. Birch PJ, Rogers H, Hayes AG, Hayward NJ, Tyers MB, Scopes DI, et al. Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist. Br J Pharmacol 1991; 103: 1819-23.
93. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA, Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007; 323: 838-45.
94. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774-6.
95. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC, Jr., et al. Antidepressant-like effects of kappaopioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323-30.
96. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA, Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 2004; 172: 463-70.
97. Carlezon WA, Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. Depressive-like effects of the kappaopioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006; 316: 440-7.
98. Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon WA, Jr. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 2001; 21: 7397-403.
99. Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 2007; 570: 89-96.
100. Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 2002; 22: 10883-90.
101. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004; 90: 1258-68.
102. Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin JP. Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology 2008; 81: 229-35.
103. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 2003; 23: 5674-83.
104. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 2006; 31: 787-94.
105. Nestler EJ, Carlezon WA, Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-9.
106. Wise RA, Bozarth MA. Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav 1982; 17: 239-43.
107. Reyes BA, Johnson AD, Glaser JD, Commons KG, Van Bockstaele EJ. Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neuroscience 2007; 145: 1077-86.
108. Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ, et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: A novel mechanism for regulating the central norepinephrine system. J Neurosci 2008; 28: 6516-25.
109. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 2008; 28: 407-14.
110. Garzon J, Rodriguez-Munoz M, de la Torre-Madrid E, Sanchez-Blazquez P. Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS. Psychopharmacology (Berl) 2005; 180: 1-11.
111. Gilchrist A. Modulating G-protein-coupled receptors: From traditional pharmacology to allosterics. Trends Pharmacol Sci 2007; 28: 431-7.
112. Garzon J, de Antonio I, Sanchez-Blazquez P. In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods Enzymol 2000; 314: 3-20.
113. Robb S, Cheek TR, Hannan FL, Hall LM, Midgley JM, Evans PD. Agonist-specific coupling of a cloned Drosophila octopa mine/tyramine receptor to multiple second messenger systems. Embo J 1994; 13: 1325-30.
114. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 2001; 54: 229-35.
115. Garzon J, Martinez-Pena Y, Sanchez-Blazquez P. Gx/z is regulated by mu but not delta opioid receptors in the stimulation of the low Km GTPase activity in mouse periaqueductal grey matter. Eur J Neurosci 1997; 9: 1194-200.
116. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 2004; 16: 711-21.
117. Garzon J, Rodriguez-Diaz M, Lopez-Fando A, Sanchez-Blazquez P. RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur J Neurosci 2001; 13: 801-11.
118. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002; 135: 1079-95.
119. Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: Evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett 2003; 343: 1-4.
120. Harkin A, Connor TJ, Burns MP, Kelly JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004; 14: 274-81.
121. Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999; 372: 207-13.
122. Kaehler ST, Singewald N, Sinner C, Philippu A. Nitric oxide modulates the release of serotonin in the rat hypothalamus. Brain Res 1999; 835: 346-9.
123. Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. NeuroReport 1993; 5: 87-9.
124. Rodriguez-Munoz M, de la Torre-Madrid E, Sanchez-Blazquez P, Wang JB, Garzon J. NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. Cell Signal 2008; 20: 1855-64.
125. Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348-54.
126. Valverde O, Mico JA, Maldonado R, Mellado M, Gibert-Rahola J. Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1073-92.
127. Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, Eschalier A. Evidence for an involvement of supraspinal delta- and spinal mu-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 2003; 307: 268-74.
128. Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998; 124: 669-74.
129. Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76: 105-14.
130. Reichenberg K, Gaillard-Plaza G, Montastruc JL. Influence of naloxone on the antinociceptive effects of some antidepressant drugs. Arch Int Pharmacodyn Ther 1985; 275: 78-85.
131. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999; 273: 85-8.
132. Berrocoso E, Rojas-Corrales MO, Mico JA. Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett 2004; 363: 25-8.
133. Devoize JL, Rigal F, Eschalier A, Trolese JF, Renoux M. Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology (Berl) 1984; 84: 71-5.
134. Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, et al. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 1987; 26: 531-9.
135. Ortega-Alvaro A, Acebes I, Saracibar G, Echevarria E, Casis L, Mico JA. Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain. Psychopharmacology (Berl) 2004; 176: 305-11.
136. Rossby SP, Nalepa I, Huang M, Perrin C, Burt AM, Schmidt DE, et al. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 1995; 687: 79-82.
137. Dziedzicka-Wasylewska M, Dlaboga D, Pierzchala-Koziec K, Rogoz Z. Effect of tianeptine and fluoxetine on the levels of Metenkephalin and mRNA encoding proenkephalin in the rat. J Physiol Pharmacol 2002; 53: 117-25.
138. Subhan F, Pache DM, Sewell RD. Potentiation of opioid-induced conditioned place preference by the selective serotonin reuptake inhibitor fluoxetine. Eur J Pharmacol 2000; 390: 137-43.
139. Hynes MD, Lochner MA, Bemis KG, Hymson DL. Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors. Life Sci 1985; 36: 2317-23.
140. de Gandarias JM, Echevarria E, Acebes I, Silio M, Casis L. Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. Arzneimittelforschung 1998; 48: 717-9.
141. de Gandarias JM, Irazusta J, Fernandez D, Varona A, Gil J, Casis L. Effect of lidocaine administration on the enkephalin-degrading aminopeptidase activities in discrete areas of the rat brain. Gen Pharmacol 1997; 29: 489-93.
142. Gallego M, Casis L, Casis O. Imipramine inhibits soluble enkephalin-degrading aminopeptidase activity in vitro. Eur J Pharmacol 1998; 360: 113-6.
143. De Felipe MC, De Ceballos ML, Gil C, Fuentes JA. Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat. Eur J Pharmacol 1985; 112: 119-22.
144. de Felipe MC, Jimenez I, Castro A, Fuentes JA. Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur J Pharmacol 1989; 159: 175-80.
145. Dziedzicka-Wasylewska M, Rogoz R. The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. J Neural Transm Gen Sect 1995; 102: 221-28.
146. Przewlocki R, Lason W, Turchan J, Przewlocka B. Imipramine induces alterations in proenkephalin and prodynorphin mRNAs level in the nucleus accumbens and striatum in the rat. Pol J Pharmacol 1997; 49: 351-5.
147. Chen Z, Yang J, Tobak A. Designing new treatments for depression and anxiety. IDrugs 2008; 11(3): 189-97.
148. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Varella EA, Nicolaides DN. Recent developments in the chemistry and in the biological applications of amidoximes. Curr Pharm Des 2008; 14(10): 1001-47.
149. Han TS, Teichert RW, Olivera BM, Bulaj G. Conus venoms - a rich source of peptide-based therapeutics. Curr Pharm Des 2008; 14(24): 2462-79